Experts involved in developing a vaccine against the emerging coronavirus in the United States fear that the Donald Trump administration will seek approval to use the drug before the November presidential election.
The New York Times, quoting informed sources, said that some employees of the departments of the American companies involved in making the vaccine are "constantly under pressure from the White House, which hopes to obtain good news." They stress that they are "afraid of political interference" in this work in the coming months.
The newspaper added: "Experts inside and outside the government fear that the White House will press the US Food and Drug Quality Administration to overlook any lack of necessary data, and urgently and urgently agree to the use of the vaccine even for specific groups of people, before the November 3 elections. ".
The article included comments from Paul Offit, a Pennsylvania State University specialist on the FDA's emerging vaccine advisory board. This specialist believes that the Washington administration may speed up the approval of the vaccine. According to the expert, some specialists are "really worried about that."